Lung cancer in patients with and without rheumatoid arthritis: A propensity score-matched survival analysis cohort study.

abstract：BACKGROUND:Breast cancer (BC) is a heterogeneous malignant tumor that threatens the health of women worldwide. Hsa_circRNA_0000518 (circ_0000518) has been revealed to be upregulated in BC tissues. However, the role and mechanism of circ_0000518 in BC are indistinct. METHODS:Quantitative real-time polymerase chain reac...

journal_title：Thoracic cancer

authors： Jiang J,Lin H,Shi S,Hong Y,Bai X,Cao X

更新日期：2020-11-01 00:00:00

abstract：:Almost all epidermal growth factor receptor (EGFR)-mutant lung cancers develop resistance to EGFR-tyrosine kinase inhibitors. Several mechanisms for this acquired resistance have been identified, including development of an EGFR T790M mutation, MET amplification, hepatocyte growth factor overexpression, loss of phosph...

journal_title：Thoracic cancer

authors： Xu S,Liu X,Liu R,Shi T,Li X,Zhong D,Wang Y,Chen G,Chen J

更新日期：2017-11-01 00:00:00

abstract：:After sternal tumor resection, reconstruction of chest wall defects is still a challenging part of thoracic surgery. Three-dimensional (3D)-printed titanium alloy prosthesis implants provide an effective solution. The bionic bone trabecular micropore structure, which is beneficial to the human body, increases stabilit...

journal_title：Thoracic cancer

authors： Wang W,Liang Z,Yang S,Feng Q,Nie X,Su G,Yuan W,Han Y

更新日期：2020-11-01 00:00:00

abstract：BACKGROUND:This study evaluated the efficacy and safety of retreatment with anti-programmed death 1 (anti-PD-1) antibodies in patients with advanced non-small cell lung cancer (NSCLC) after prior treatment with anti-programmed death-ligand 1 (anti-PD-L1) antibodies. METHODS:Data (N = 15) on patients' characteristics, ...

journal_title：Thoracic cancer

authors： Fujita K,Yamamoto Y,Kanai O,Okamura M,Hashimoto M,Nakatani K,Sawai S,Mio T

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:Lung cancer is a disease with a poor prognosis and psychological impact. Lung cancer causes both physical and psychological burdens on patients, and financial burdens on families and society. The aim of this study was to examine the relationship between depression and influencing factors in non-small-cell lu...

journal_title：Thoracic cancer

authors： Shi Y,Gu F,Hou LL,Hu YQ

更新日期：2015-05-01 00:00:00

abstract：BACKGROUND:Epidermal growth factor-tyrosine kinase inhibitors (EGFR-TKIs) are one of the effective medicines in advanced lung adenocarcinoma leptomeningeal metastasis (LM) treatment in recent years. METHODS:This paper reports two cases of advanced lung adenocarcinoma with exon-EGFR19 mutation. LM occurred during gefit...

journal_title：Thoracic cancer

authors： Xing P,Li J,Shi Y,Zhang X

更新日期：2014-01-01 00:00:00

abstract：:A squamous cell lung cancer patient was treated with pneumonectomy. A recurrent lung cancer (adenocarcinoma) was found 45 months later and successfully biopsied and treated with microwave ablation. After 18 months of follow up, no evidence of tumor recurrence was observed. ...

journal_title：Thoracic cancer

authors： Wei Z,Wang J,Ye X,Yang X,Huang G

更新日期：2016-01-01 00:00:00

abstract：:Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. The unique spectrum of immune-related adverse events (IrAEs) may occur during treatment. Dermatologic toxicities appear to be one of the most prevalent immunotherapy-related adverse events. The most common symptoms are maculopapular rash and pru...

journal_title：Thoracic cancer

authors： Si X,He C,Zhang L,Liu X,Li Y,Wang H,Guo X,Zhou J,Duan L,Wang M,Zhang L

更新日期：2020-02-01 00:00:00

abstract：:Immune checkpoint inhibitors (ICIs) have been widely used in the management of malignant tumors. Programmed death 1 (PD-1)/PD-1 ligand (PD-L1) inhibitors have been introduced to treat non-small cell lung cancer (NSCLC) in recent years. Currently, PD-1/PD-L1 inhibitors are considered to have minor side effects and do n...

journal_title：Thoracic cancer

authors： Lu M,Zhang L,Li Y,Wang H,Guo X,Zhou J,Duan L,Si X,Xu Y,Zhang L

更新日期：2020-03-01 00:00:00

abstract：:Atezolizumab was the first immune checkpoint inhibitor (ICI) to be introduced as a first-line treatment option for extensive-stage small cell lung cancer (ES-SCLC), in combination with carboplatin and etoposide (CE) chemotherapy. However, SCLC treatment options after progression to first-line chemotherapy are limited,...

journal_title：Thoracic cancer

authors： Kataoka N,Kunimatsu Y,Tachibana Y,Sugimoto T,Sato I,Tani N,Ogura Y,Hirose K,Takeda T

更新日期：2020-09-01 00:00:00

abstract：:Pulmonary pleomorphic carcinoma has been shown to respond remarkably to PD-1 inhibitors; however, the biomarkers for this therapy have not been fully proven. We report a case of pulmonary pleomorphic carcinoma with overexpressed PD-L1, in which a complete response to nivolumab was sustained for >14 months. Immunohisto...

journal_title：Thoracic cancer

authors： Okamura K,Fukuda Y,Soda H,Ogawara D,Iwasaki K,Fuchi S,Suyama T,Yoshida M,Harada T,Fukuda M,Mukae H

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:This study aimed to compare survival between standard lobectomy and surgeons' preference sublobar resection among patients with stage I non-small cell lung cancer (NSCLC). METHODS:Medical records of patients undergoing pulmonary resection between 2006 and 2016 were reviewed retrospectively. Differences in d...

journal_title：Thoracic cancer

authors： Huang CS,Hsu PK,Chen CK,Yeh YC,Hsu HS,Shih CC,Huang BS

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:Accumulated evidence has revealed that the dysregulation of micro ribonucleic acids (miRNAs) may contribute to esophageal squamous cell carcinoma (ESCC). MiR-93, which is a member of the miRNA cluster miR-106b∼25, has been widely studied for its tumor promoting effect on different types of cancers. However, ...

journal_title：Thoracic cancer

authors： Li C,Ding C,Chen T,Chen J,Xu Z,Lei Z,Xu C,Zhao J

更新日期：2015-07-01 00:00:00

abstract：BACKGROUND:To distinguish early-stage lung cancer from benign disease in pulmonary nodules, especially lesions with ground-glass opacity (GGO), we assessed gene mutations of ctDNA in peripheral blood using targeted next-generation sequencing (NGS). METHODS:Single pulmonary nodule patients without mediastinal lymph nod...

journal_title：Thoracic cancer

authors： Jiang N,Zhou J,Zhang W,Li P,Liu Y,Shi H,Zhang C,Wang Y,Zhou C,Peng C,Zhang W,Hao Y,Sun Q,Li Y,Zhao X

更新日期：2020-11-16 00:00:00

abstract：:Immune checkpoint inhibitors that block the programmed death 1/programmed death ligand 1 pathways are widely used to treat advanced lung cancers. There are seldom cases of histologic transformation reported after treatment with immunotherapy. Here, we report the case of a 69-year-old man with stage IV lung squamous ce...

journal_title：Thoracic cancer

authors： Si X,You Y,Zhang X,Wang H,Wang M,Zhang L

更新日期：2020-03-01 00:00:00

abstract：BACKGROUND:We explored correlations between the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification, epidermal growth factor receptor (EGFR) mutation status, and prognosis. METHODS:Data from 293 patients with lung adenocarcinoma were classifi...

journal_title：Thoracic cancer

authors： Guo Z,Yi F,Yin W,Zhang Y,Li Q,Gu Y,Xiao Y,Cao B,Ma L,Liang L

更新日期：2017-05-01 00:00:00

abstract：:Here, we report two cases of advanced non-small cell lung cancer (NSCLC) in patients with negative driver genes who received ICI treatment for less than two years but continued to benefit from their administration after drug withdrawal. The first patient was diagnosed with left lung adenocarcinoma, cT1cN3M1c, stage IV...

journal_title：Thoracic cancer

authors： Shan Q,Wang H,Han X,Guo J,Wang Z

更新日期：2020-10-01 00:00:00

abstract：:A 69-year-old woman visited our hospital complaining of right chest pain. Chest computed tomography showed a 55 × 45 mm tumor in the right upper lobe. Bronchoscopy revealed displaced anomalous B 1 and B 2+3 arising from the right main bronchus, and the patient was diagnosed with lung adenocarcinoma by transbronchial l...

journal_title：Thoracic cancer

authors： Tajima K,Uchida N,Sasamoto H,Okada T,Kohri T,Mogi A,Kuwano H

更新日期：2016-09-01 00:00:00

abstract：:A clinical trial of immune checkpoint inhibitors for advanced non-small cell lung cancer reported an overall survival plateau with a long tail to the survival curve, suggesting that immune checkpoint inhibitors prolong survival. However, little evidence supports the efficacy of immune checkpoint inhibitors as neoadjuv...

journal_title：Thoracic cancer

authors： Sumi T,Uehara H,Masaoka T,Tada M,Keira Y,Kamada K,Shijubou N,Yamada Y,Nakata H,Mori Y,Chiba H

更新日期：2020-11-01 00:00:00

abstract：BACKGROUND:In cases of EGFR-tyrosine kinase inhibitor (TKI) failure, re-biopsy may be useful to understand resistance mechanisms and guide further treatment decisions. However, performing re-biopsy is challenging because of several hurdles. We assessed the feasibility of re-biopsy in advanced non-small cell lung cancer...

journal_title：Thoracic cancer

authors： Kim TO,Oh IJ,Kho BG,Park HY,Chang JS,Park CK,Shin HJ,Lim JH,Kwon YS,Kim YI,Lim SC,Kim YC,Choi YD

更新日期：2018-07-01 00:00:00

abstract：BACKGROUND:To investigate the correlation between mesenchymal-epithelial transition factor (C-Met) and human epidermal growth receptor 2 (HER2) protein expression in primary lung adenocarcinoma tissues. METHOD:A total of 1479 resected primary lung adenocarcinoma patients were enrolled in the present study for detectin...

journal_title：Thoracic cancer

authors： Yang L,Che Y,Guo L,Zheng B,Wang B,Yang Z,Zhu Y,Li J

更新日期：2018-04-01 00:00:00

abstract：BACKGROUND:If anaplastic lymphoma kinase (ALK) gene rearrangement in lung cancer is identified, ALK-tyrosine kinase inhibitors (ALK-TKIs) can be an effective treatment. However, the details of drug-induced lung injury (DILI) caused by ALK-TKI, which can be a serious side effect of ALK-TKIs, remains unclear. This study ...

journal_title：Thoracic cancer

authors： Koshikawa K,Terada J,Abe M,Iwasawa S,Sakayori M,Yoshioka K,Hirasawa Y,Kasai H,Kawasaki Y,Tsushima K,Tatsumi K

更新日期：2020-06-01 00:00:00

abstract：BACKGROUND:Despite recent advances in treating non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs), their role in ALK-positive NSCLC patients is unclear. We investigated the efficacy of ICIs in patients with ALK-positive NSCLC. METHODS:Between 2011 and 2018, a total of 14 ALK-positive NSCLC pat...

journal_title：Thoracic cancer

authors： Heo JY,Park C,Keam B,Ock CY,Kim M,Kim TM,Kim DW,Kim SH,Kim YJ,Lee JS,Heo DS

更新日期：2019-11-01 00:00:00

abstract：:Pleomorphic adenoma is the most common type of salivary gland tumor. Although it rarely affects the trachea and bronchus, it usually grows in the airway and presents as an endobronchial mass. We recently experienced a case of pleomorphic adenoma originating in the bronchus and growing outward into the mediastinum. We ...

journal_title：Thoracic cancer

authors： Lee YK,Kim YH,Kim GY,Youn HC

更新日期：2014-01-01 00:00:00

abstract：BACKGROUND:  The optimal strategy was not established for patients who initially responded to gefitinib although re-administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been proven to be an option. Gefitinib and erlotinib were compared as salvage treatment after gefitinib fail...

journal_title：Thoracic cancer

authors： Yu S,Wang Y,Li J,Hao X,Wang B,Wang Z,Zhang X,Shi Y

更新日期：2013-05-01 00:00:00

abstract：:This report describes the surgical management of a male patient with early-stage lung cancer who underwent thoracoscopic completion right lower lobectomy after previously undergoing sublobar resection for multifocal ground glass nodules of the lung. Perioperative considerations associated with the management of dense ...

journal_title：Thoracic cancer

authors： Liu YW,Chou SH,Hung JY,Kao CN,Chang PC

更新日期：2019-05-01 00:00:00

abstract：BACKGROUND:This meta-analysis was conducted to investigate the diagnostic performance of P16INK4a gene promoter methylation as a biomarker of non-small cell lung cancer (NSCLC). METHODS:Two reviewers independently searched the Web of Science, PubMed, Cochrane, Embase, China National Knowledge Infrastructure, and Chine...

journal_title：Thoracic cancer

authors： Tuo L,Sha S,Huayu Z,Du K

更新日期：2018-08-01 00:00:00

abstract：BACKGROUND:S-1 monotherapy is effective and feasible for previously treated patients with advanced non-small cell lung cancer (NSCLC). However, it is not clear whether its effectiveness and tolerability in elderly patients are equivalent to those in younger patients. Hence, this study aimed to evaluate the efficacy and...

journal_title：Thoracic cancer

authors： Imai H,Minemura H,Kishikawa T,Yamada Y,Suzuki K,Umeda Y,Wasamoto S,Kasahara N,Ishihara S,Yamaguchi O,Naruse I,Uchino J,Mori K,Kanazawa K,Shibata Y,Kasai T,Kaburagi T,Kaira K,Minato K

更新日期：2020-10-01 00:00:00

abstract：BACKGROUND:Various polymorphisms have been detected in the UDP-glucuronosyltransferase 1A ( UGT1A ) gene, and UGT1A1 *28 and UGT1A1 *6 have important effects on the pharmacokinetics of irinotecan and the risk of severe toxicities during irinotecan therapy. This study was conducted to determine the maximum tolerated dos...

journal_title：Thoracic cancer

authors： Fukuda M,Shimada M,Kitazaki T,Nagashima S,Hashiguchi K,Ebi N,Takayama K,Nakanishi Y,Semba H,Harada T,Seto T,Okamoto I,Ichinose Y,Sugio K

更新日期：2017-01-01 00:00:00

abstract：:ROS1 rearrangement is a validated therapeutic driver gene in non-small cell lung cancer (NSCLC) and represents a small subset (1-2%) of NSCLC. A total of 17 different fusion partner genes of ROS1 in NSCLC have been reported. The multi-targeted MET/ALK/ROS1 tyrosine kinase inhibitor (TKI) crizotinib has demonstrated re...

journal_title：Thoracic cancer

authors： Zhu YC,Zhou YF,Wang WX,Xu CW,Zhuang W,Du KQ,Chen G

更新日期：2018-05-01 00:00:00